Abstract
Epilepsy is a serious brain condition characterized by recurring seizures. It affects millions of people across the globe. Much advancement in the past has improved the understanding of the underlying pathophysiology and risk factors for epilepsy. These advances have led to the development of both new terminologies and classification as well as treatment strategies for the disease. Despite the fact that various antiepileptic drugs have been developed in past decades, major part of affected population remains either resistant or refractory to the currently available therapy. Also, none of these anticonvulsant agents are devoid of serious side effect. Therefore, constant efforts are being made to develop antiepileptic drugs with improved efficacy and better pharmacokinetic and safety profile. The new structural classes which are being developed broadly amides, amino acids and a number of heterocyclic agents like oxadiazoles, benzimidazoles, benzothazoles, pyrazoles, indoles and benzothaizoles etc. These new compounds have potential for identification of novel targets and drug development. This review makes a note of these issues and describes recent developments in antiepileptic drug discovery.
Keywords: Antiepileptic drugs, epilepsy, heterocycles, seizure, tonic-clonic.
Mini-Reviews in Medicinal Chemistry
Title:Past, Present and Future of Antiepileptic Drug Therapy - Finding a Place for Heterocyclics
Volume: 15 Issue: 12
Author(s): Ruhi Ali, Mohammad Ahmed Khan and Nadeem Siddiqui
Affiliation:
Keywords: Antiepileptic drugs, epilepsy, heterocycles, seizure, tonic-clonic.
Abstract: Epilepsy is a serious brain condition characterized by recurring seizures. It affects millions of people across the globe. Much advancement in the past has improved the understanding of the underlying pathophysiology and risk factors for epilepsy. These advances have led to the development of both new terminologies and classification as well as treatment strategies for the disease. Despite the fact that various antiepileptic drugs have been developed in past decades, major part of affected population remains either resistant or refractory to the currently available therapy. Also, none of these anticonvulsant agents are devoid of serious side effect. Therefore, constant efforts are being made to develop antiepileptic drugs with improved efficacy and better pharmacokinetic and safety profile. The new structural classes which are being developed broadly amides, amino acids and a number of heterocyclic agents like oxadiazoles, benzimidazoles, benzothazoles, pyrazoles, indoles and benzothaizoles etc. These new compounds have potential for identification of novel targets and drug development. This review makes a note of these issues and describes recent developments in antiepileptic drug discovery.
Export Options
About this article
Cite this article as:
Ali Ruhi, Khan Ahmed Mohammad and Siddiqui Nadeem, Past, Present and Future of Antiepileptic Drug Therapy - Finding a Place for Heterocyclics, Mini-Reviews in Medicinal Chemistry 2015; 15 (12) . https://dx.doi.org/10.2174/138955751512150731113549
DOI https://dx.doi.org/10.2174/138955751512150731113549 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Activity-Dependent Release of Adenosine: A Critical Re-Evaluation of Mechanism
Current Neuropharmacology The Role of Neuroimaging in Our Understanding of the Suicidal Brain
CNS & Neurological Disorders - Drug Targets Securinine Derivatives as Potential Anti-amyloid Therapeutic Approach
CNS & Neurological Disorders - Drug Targets Breath-Holding Spells in Pediatrics: A Narrative Review of the Current Evidence
Current Pediatric Reviews Gene and Gene-Environment Risk Factors in Sudden Undexpected Death in Infants
Current Pediatric Reviews GABAergic Agonists Modulate the Glutamate Release from Frontal Cortex Synaptosomes of Rats with Experimental Autoimmune Encephalomyelitis
Inflammation & Allergy - Drug Targets (Discontinued) Glycogen Metabolism and Brain Pathologies
Central Nervous System Agents in Medicinal Chemistry Alpha-7 Nicotinic Receptors in Nervous System Disorders: From Function to Therapeutic Perspectives
Central Nervous System Agents in Medicinal Chemistry NAP (Davunetide) Provides Functional and Structural Neuroprotection
Current Pharmaceutical Design Minimizing AED Adverse Effects: Improving Quality of Life in the Interictal State in Epilepsy Care
Current Neuropharmacology Synthesis, Anticonvulsant and Neurotoxicity Evaluation of Some Newer N-(2-benzoylbenzofuran-3-yl)-3-(substituted)-propanamide Analogs
Central Nervous System Agents in Medicinal Chemistry Vagus Nerve Stimulation as a Treatment for Refractory Epilepsy: A 15-Year Experience in an Italian Tertiary – Care Epilepsy Center
Letters in Drug Design & Discovery Patent Annotations
Recent Patents on Anti-Cancer Drug Discovery Crosstalk Between Calpain and Calcineurin in Excitotoxic Neurodegeneration; Therapeutic Targets for the Treatment of Excitotoxic Neurodegeneration
Current Medicinal Chemistry - Central Nervous System Agents Neuroinflammation, Diabetes and COVID-19: Perspectives Coming from Ca<sup>2+</sup>/cAMP Signalling
Current Drug Research Reviews Dysregulation of SIRT-1 Signaling in Multiple Sclerosis and Neuroimmune Disorders: A Systematic Review of SIRTUIN Activators as Potential Immunomodulators and their Influences on other Dysfunctions
Endocrine, Metabolic & Immune Disorders - Drug Targets Approaching Inherited Disease on a Genomic Scale
Current Genomics Hepatic Effects of Duloxetine-I: Non-Clinical and Clinical Trial Data
Current Drug Safety Hybrid Imaging: Conclusions and Perspectives
Current Medical Imaging Carbonic Anhydrase I and II Inhibition with Natural Products: Abrus precatorius
Current Enzyme Inhibition